Roots Analysis identifies top five RSV vaccine manufacturers
A recent market study from Roots Analysis identifies five companies leading the development and production of respiratory syncytial virus vaccines to address rising global demand.
A comprehensive industry report by Roots Analysis has identified five major companies driving the development of respiratory syncytial virus (RSV) vaccines. The list includes Icosavax—now part of AstraZeneca—Moderna, Pfizer, GlaxoSmithKline, and Sanofi. This analysis highlights how these entities are responding to the high global burden of RSV, which causes millions of infections annually, particularly among infants and the elderly.
Historically, RSV management has been limited to symptomatic treatments such as humidifiers and nasal sprays. However, the rise of specialized vaccine technology has changed the treatment landscape. The report notes that these companies are utilizing diverse approaches, ranging from VLP (viral-like particle) technology to mRNA platforms, to provide targeted immune protection.
The research underscores a shift toward preventive care, supported by a significant increase in clinical trial activity. With dozens of manufacturers currently working in this space, Roots Analysis aims to provide stakeholders with insights into market trends and the long-term potential for public health improvements through immunization. The full study covers approximately 70 players engaged in the field.